Literature DB >> 26711022

Frequent presence of hepaci and pegiviruses in commercial equine serum pools.

Alexander Postel1, Jessika-M V Cavalleri2, Stephanie Pfaender3, Stephanie Walter3, Eike Steinmann3, Nicole Fischer4, Karsten Feige2, Ludwig Haas1, Paul Becher5.   

Abstract

Novel viruses belonging to the genera Hepacivirus and Pegivirus have recently been discovered in horses and other animal species. Viral genomes of non-primate hepaciviruses (NPHV), equine pegivirus 1 (EPgV 1) and Theiler's disease associated virus (TDAV) were detected in a horse serum routinely used for cell culture propagation in our laboratory. Therefore, a study was carried out to further investigate the presence of these human Hepatitis C virus (HCV) related viruses in equine serum based products used in veterinary medicine and for research and to characterize the viral genomes. Without exception all commercially available equine sera purchased for cell culture propagation (n=6) were tested positive for NPHV, EPgV 1 or TDAV genomes by qRT-PCR. Molecular analyses of one single commercial horse serum from Europe confirmed multiple viral genomes, including two TDAV genomes significantly different from the only published TDAV sequence. Furthermore, multiple batches of horse serum pools (n=35) collected for manufacturing of biological products turned out to be positive for NPHV and EPgV 1 genomes. Nevertheless, the final commercial products (n=9) were exclusively tested qRT-PCR negative. Field samples (n=119) obtained from two premises located in the same region as the donor horses were analyzed, demonstrating the frequent presence of NPHV and EPgV 1, but the absence of TDAV genomes. The presence of NPHV, EPgV 1 and TDAV in commercial equine sera and serum based products could have considerable consequences for biosecurity and may also bias the outcome of research studies conducted with related viruses.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biosecurity; Commercial sera; Equine pegivirus 1 (EPg V 1); Horse; Non-primate hepacivirus (NPHV); Prevalence; Real-time RT-PCR; Theiler’s Disease Associated Virus (TDAV)

Mesh:

Year:  2015        PMID: 26711022     DOI: 10.1016/j.vetmic.2015.10.032

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  12 in total

Review 1.  The Strange, Expanding World of Animal Hepaciviruses.

Authors:  Alex S Hartlage; John M Cullen; Amit Kapoor
Journal:  Annu Rev Virol       Date:  2016-09-29       Impact factor: 10.431

2.  Immune protection against reinfection with nonprimate hepacivirus.

Authors:  Stephanie Pfaender; Stephanie Walter; Elena Grabski; Daniel Todt; Janina Bruening; Inés Romero-Brey; Theresa Gather; Richard J P Brown; Kerstin Hahn; Christina Puff; Vanessa M Pfankuche; Florian Hansmann; Alexander Postel; Paul Becher; Volker Thiel; Ulrich Kalinke; Bettina Wagner; Ralf Bartenschlager; Wolfgang Baumgärtner; Karsten Feige; Thomas Pietschmann; Jessika M V Cavalleri; Eike Steinmann
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-08       Impact factor: 11.205

3.  Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis.

Authors:  Joy E Tomlinson; Raphael Wolfisberg; Ulrik Fahnøe; Himanshu Sharma; Randall W Renshaw; Louise Nielsen; Eiko Nishiuchi; Christina Holm; Edward Dubovi; Brad R Rosenberg; Bud C Tennant; Jens Bukh; Amit Kapoor; Thomas J Divers; Charles M Rice; Gerlinde R Van de Walle; Troels K H Scheel
Journal:  PLoS Pathog       Date:  2020-07-10       Impact factor: 6.823

4.  Equine Parvovirus-Hepatitis Frequently Detectable in Commercial Equine Serum Pools.

Authors:  Toni Luise Meister; Birthe Tegtmeyer; Alexander Postel; Jessika-M V Cavalleri; Daniel Todt; Alexander Stang; Eike Steinmann
Journal:  Viruses       Date:  2019-05-21       Impact factor: 5.048

5.  Viral testing of 18 consecutive cases of equine serum hepatitis: A prospective study (2014-2018).

Authors:  Joy E Tomlinson; Amit Kapoor; Arvind Kumar; Bud C Tennant; Melissa A Laverack; Laurie Beard; Katie Delph; Elizabeth Davis; Harold Schott Ii; Kara Lascola; Todd C Holbrook; Philip Johnson; Sandra D Taylor; Erica McKenzie; Jessica Carter-Arnold; Emilie Setlakwe; Lisa Fultz; Jeff Brakenhoff; Rebecca Ruby; Sheetal Trivedi; Gerlinde R Van de Walle; Randall W Renshaw; Edward J Dubovi; Thomas J Divers
Journal:  J Vet Intern Med       Date:  2018-12-05       Impact factor: 3.333

6.  Further Evidence for in Utero Transmission of Equine Hepacivirus to Foals.

Authors:  Stephane Pronost; Christine Fortier; Christel Marcillaud-Pitel; Jackie Tapprest; Marc Foursin; Bertrand Saunier; Pierre-Hugues Pitel; Romain Paillot; Erika S Hue
Journal:  Viruses       Date:  2019-12-05       Impact factor: 5.048

7.  No Evidence of Mosquito Involvement in the Transmission of Equine Hepacivirus (Flaviviridae) in an Epidemiological Survey of Austrian Horses.

Authors:  Marcha Badenhorst; Phebe de Heus; Angelika Auer; Till Rümenapf; Birthe Tegtmeyer; Jolanta Kolodziejek; Norbert Nowotny; Eike Steinmann; Jessika-M V Cavalleri
Journal:  Viruses       Date:  2019-11-01       Impact factor: 5.048

8.  First Description of Hepacivirus and Pegivirus Infection in Domestic Horses in China: A Study in Guangdong Province, Heilongjiang Province and Hong Kong District.

Authors:  Gang Lu; Lingshuang Sun; Tao Xu; Dong He; Zengchao Wang; Shudan Ou; Kun Jia; Liguo Yuan; Shoujun Li
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

9.  Identification and genetic characterization of hepacivirus and pegivirus in commercial equine serum products in China.

Authors:  Gang Lu; Ji Huang; Qiliang Yang; Haibin Xu; Peixin Wu; Cheng Fu; Shoujun Li
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

10.  Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family.

Authors:  Donald B Smith; Paul Becher; Jens Bukh; Ernest A Gould; Gregor Meyers; Thomas Monath; A Scott Muerhoff; Alexander Pletnev; Rebecca Rico-Hesse; Jack T Stapleton; Peter Simmonds
Journal:  J Gen Virol       Date:  2016-09-28       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.